Read more about the article @AllogeneTx: Please join us for an update on our AlloCAR TTM platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO

@AllogeneTx: Please join us for an update on our AlloCAR TTM platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO

Please join us for an update on our AlloCAR TTM platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details…

Continue Reading@AllogeneTx: Please join us for an update on our AlloCAR TTM platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO
Read more about the article Please join us for an update on our AlloCAR TTM platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO https://t.co/GxYMTm2niZ

Please join us for an update on our AlloCAR TTM platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO https://t.co/GxYMTm2niZ

Please join us for an update on our AlloCAR TTM platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details…

Continue ReadingPlease join us for an update on our AlloCAR TTM platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO https://t.co/GxYMTm2niZ
Read more about the article @AllogeneTx: This month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.

@AllogeneTx: This month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.

This month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.— Allogene Therapeutics (@AllogeneTx)…

Continue Reading@AllogeneTx: This month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.
Read more about the article @AllogeneTx: This month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.

@AllogeneTx: This month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.

This month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.— Allogene Therapeutics (@AllogeneTx)…

Continue Reading@AllogeneTx: This month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.
Read more about the article This month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.

This month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.

This month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.— Allogene Therapeutics (@AllogeneTx)…

Continue ReadingThis month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.